Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

Phase 1/2 Terminated 2 enrolled Baptist Health South Florida University of California, Los Angeles · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label unblinded, randomized study to treat hospitalized covid-19 patients with colchicine plus current care (per institution treating physicians) vs. current care per institution treating physicians alone (the control arm)

Timeline

Start: 2020-12-23
Primary completion: 2021-05-12
Completion: 2021-09-20

Outcome

Outcome not reported

Stopped (Enrollment): “Recovery Trial showed no convincing evidence that further recruitment would provide conclusive proof of worthwhile benefit for the evaluation of Colchicine in patients with Covid-19.”

Publications

Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI, Becker M, Dorando E, Pacheco RL, Martimbianco ALC, Riera R, Skoetz N, Stegemann M. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Colchicine	Small molecule	0.6 mg	Oral